&lt;p&gt;Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells&lt;/p&gt;

Ma, Li; Cao, Xinyu; Ye, Xiaotong; Ye, Jianping; Sun, Yongning

doi:10.2147/dmso.s247251

Cited by 6 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aqueous extract of senna improves metabolic abnormalities linked with diabetes and reduces chronic hyperglycemia-related complications in streptozotocin-induced diabetic rats [17,35]. In our experiment, glucose utilization was improved by S. alexandrina leaf powder supplementation, which is supported by a previous study [36].…”

Section: Discussionsupporting

confidence: 85%

Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats

et al. 2021

View full text Add to dashboard Cite

Obesity is an enduring medical issue that has raised concerns around the world. Natural plant extracts have shown therapeutic potential in preventing oxidative stress and inflammation related to obesity complications. In this study, Senna alexandrina Mill. leaves were utilized to treat high-fat diet-related metabolic disorders and non-alcoholic fatty liver diseases. Plasma biochemical assays were conducted to determine the lipid profiles and oxidative stress parameters, and the gene expression of antioxidant enzymes and inflammatory mediators was measured. Histological stained livers of high-fat diet-fed rats were observed. S. alexandrina leaf powder supplementation prevented the increase in cholesterol and triglyceride levels in high-fat diet-fed rats. Moreover, S. alexandrina leaves also reduced lipid peroxidation and nitric oxide production in these rats. Prevention of oxidative stress by S. alexandrina leaf supplementation in high-fat diet-fed rats is regulated by enhancing the antioxidant enzyme activity, followed by the restoration of corresponding gene expressions, such as NRF-2, HO-1, SOD, and CAT. Histological staining provides further evidence that S. alexandrina leaf supplementation prevents inflammatory cell infiltration, lipid droplet deposition, and fibrosis in the liver of high-fat diet-fed rats. Furthermore, this investigation revealed that S. alexandrina leaf supplementation controlled non-alcoholic fatty liver disease by modulating the expression of fat metabolizing enzymes in high-fat diet-fed rats. Therefore, S. alexandrina leaf supplementation inhibits fatty liver inflammation and fibrosis, suggesting its usefulness in treating non-alcoholic steatohepatitis. Thus, this natural leaf extract has potential in treatment of obesity related liver dysfunction.

show abstract

Section: Discussionsupporting

confidence: 85%

Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We found that metoclopramide (a prokinetic agent) was associated with a higher BG at 4 hours while sennosides and bisacodyl were associated with a lower BG. Sennosides A, the active ingredient in sennosides, demonstrated the ability to stimulate intestinal cells to secrete GLP-1 and alter the gut microbiota 49 , leading to improved insulin sensitivity in mice 50,51 . Sennosides A was also shown to have similar potency as acarbose in alpha-glucoamylase inhibition.…”

Section: Discussionmentioning

confidence: 99%

Medications that Regulate Gastrointestinal Transit Influence Inpatient Blood Glucose

Momenzadeh,

Cranney,

Choi

et al. 2024

Preprint

View full text Add to dashboard Cite

ObjectiveA multitude of factors affect a hospitalized individual’s blood glucose (BG), making BG difficult to predict and manage. Beyond medications well established to alter BG, such as beta-blockers, there are likely many medications with undiscovered effects on BG variability. Identification of these medications and the strength and timing of these relationships has potential to improve glycemic management and patient safety.Materials and MethodsEHR data from 103,871 inpatient encounters over 8 years within a large, urban health system was used to extract over 500 medications, laboratory measurements, and clinical predictors of BG. Feature selection was performed using an optimized Lasso model with repeated 5-fold cross-validation on the 80% training set, followed by a linear mixed regression model to evaluate statistical significance. Significant medication predictors were then evaluated for novelty against a comprehensive adverse drug event database.ResultsWe found 29 statistically significant features associated with BG; 24 were medications including 10 medications not previously documented to alter BG. The remaining five factors were Black/African American race, history of type 2 diabetes mellitus, prior BG (mean and last) and creatinine.DiscussionThe unexpected medications, including several agents involved in gastrointestinal motility, found to affect BG were supported by available studies. This study may bring to light medications to use with caution in individuals with hyper- or hypoglycemia. Further investigation of these potential candidates is needed to enhance clinical utility of these findings.ConclusionThis study uniquely identifies medications involved in gastrointestinal transit to be predictors of BG that may not well established and recognized in clinical practice.

show abstract

“…Consistently, Ma et al demonstrated that SA (45 mg/kg in vivo and 100 μM in vitro ) stimulated the secretion of GLP-1 in L cells by activating ERK1/2 pathway and improving the expression of PC1/3 protein, which might be the main mechanism of improving insulin sensitivity. However, the activation mechanism of ERK1/2 and its effect on PC1/3 have not been elaborated in detail ( Ma et al, 2020b ).…”

Section: Pharmacologymentioning

confidence: 99%

Pharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound

Zhou

et al. 2021

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Sennoside A (SA) is a natural dianthrone glycoside mainly from medicinal plants of Senna and Rhubarb, and used as a folk traditional irritant laxative and slimming health food. Accumulating evidences suggest that SA possesses numerous pharmacological properties, such as laxative, anti-obesity, hypoglycemic, hepatoprotective, anti-fibrotic, anti-inflammatory, anti-tumor, anti-bacterial, anti-fungal, anti-viral, and anti-neurodegenerative activities. These pharmacological effects lay the foundation for its potential application in treating a variety of diseases. However, numerous published studies suggest that a long-term use of SA in large doses may have some adverse effects, including the occurrence of melanosis coli and carcinogenesis of colon cancer, thereby limiting its clinical use. It remains to be established whether SA or its metabolites are responsible for the pharmacological and toxicity effects. In this review, the latest advances in the pharmacology, toxicology, and metabolism of SA were summarizedbased on its biological characteristics and mechanism.

show abstract

<p>Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells</p>

Cited by 6 publications

References 27 publications

Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats

Leaf powder supplementation of Senna alexandrina ameliorates oxidative stress, inflammation, and hepatic steatosis in high-fat diet-fed obese rats

Medications that Regulate Gastrointestinal Transit Influence Inpatient Blood Glucose

Pharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound

Contact Info

Product

Resources

About